New combo therapy shows promise for common lung cancer mutation
NCT ID NCT06376084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how well the drug osimertinib combined with chemotherapy works as the first treatment for people with advanced EGFR-mutant non-small cell lung cancer. It involves 532 adults with stage IIIB, IIIC, or IV disease who cannot have surgery or radiation. Researchers are tracking how long patients live without the cancer getting worse and how long they live overall in real-world settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRONCHIAL NEOPLASMS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Shanghai, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Cutting radiation in CT scans: a new test of Ultra-Low-Dose imaging
- Can a simple CT scan catch lung cancer earlier in kuwait?
- A simple screening program could transform cancer aftercare
- A new program aims to ease the 'Lost in Transition' struggle for cancer survivors
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can a new immune drug outsmart Hard-to-Treat tumors?